| Name | Title | Contact Details |
|---|
Delfi is developing a new class of liquid biopsy tests for early detection based on altered genome-wide fragmentation profiles, also known as "fragmentomes," representing aberrant packaging of DNA in cancer cells. By applying advanced machine learning algorithms, these fragment patterns are detectable at a very low sequencing cost. Delfi is using this technology to develop highly sensitive and specific cancer detection assays intended for wide and cost-effective distribution and adoption.
A large molecule CRO combining world-class protein chemistry expertise, integrated large molecule analytical services, and coagulation reagents for biopharma R&D.
Anthos Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of genetically and pharmacologically validated innovative therapies to advance care for people living with cardiovascular and metabolic (CVM) diseases. Anthos Therapeutics aims to combine the agility of a biotech with the rigor of a large pharmaceutical company. Anthos Therapeutics was launched by Blackstone Life Sciences in 2019.
DMS Provides Mobile, Interim, and Fixed-Site Diagnostic Imaging Services and Medical Equipment Sales, Service, Parts, Rentals.
Stemline Therapeutics is a clinical stage biopharmaceutical company developing oncology compounds that target cancer stem cells.